Sanofi American Depositary Receipt (SNY)
Callodine Capital Management LP Purchases 182,837 Shares of Sanofi $SNY
Callodine Capital Management LP grew its stake in Sanofi (NASDAQ: SNY) by 35.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 698,046 shares of the company's stock after acquiring an additional 182,837 shares during the period. Sanofi accounts for
Need Growing EPS And Dividends? Prescribe Sanofi
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixent and a strong pipeline, supporting consensus EPS growth of 9.3% annually through 2028. SNY offers a 5.1% dividend yield, backed by 31 consecutive annual increases and a sustainable payout ratio in the high-40% range.
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions
Texas Attorney General Ken Paxton on Thursday sued Sanofi for allegedly "bribing" providers to prescribe its medications over alternatives.
Drugmaker Sanofi to expand India GCC, increase workforce to over 4,500 employees
French drugmaker Sanofi said on Monday it will expand its global capability centre (GCC) in the southern Indian city of Hyderabad, and increase its workforce to more than 4,500 employees.
SNY Stock Falls After Board Suddenly Makes Leadership Change
Sanofi stock slides 4.5% after it decides not to renew CEO Paul Hudson's mandate and names Belen Garijo as successor amid investor skepticism.
Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued
Sanofi reported FY net sales up >9% to €43.6bn and net income up >12% to €9.5mn. Despite strong results, Sanofi announced today it has replaced CEO Paul Hudson with former employee Belén Garijo, signaling urgency for improved execution and R&D innovation. Sanofi remains heavily reliant on Dupixent, which generated ~€15.7bn, or 36% of total 2024 revenues.
Who is Sanofi's new CEO Belén Garijo?
French drugmaker Sanofi on Thursday appointed Belén Garijo as its new chief executive after choosing not to renew the mandate of Paul Hudson.
Sanofi Names Merck KGaA's Garijo to Replace Hudson as CEO
Garijo steps in after the drugmaker's board of directors decided not to renew Hudson's mandate.
Sanofi appoints Belén Garijo as new CEO after deciding not to renew current CEO Hudson's mandate
French drugmaker Sanofi said on Thursday it had appointed Belén Garijo as its new chief executive after deciding not to renew the mandate of current CEO Paul Hudson.
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status
Sanofi wins FDA Breakthrough Therapy and Japan Orphan designations for Wayrilz in wAIHA, backed by LUMINA data and a late-stage study.
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
